{
    "nct_id": "NCT05216835",
    "official_title": "A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.",
    "inclusion_criteria": "* ≥ 16 years of age at the time of obtaining informed consent\n* Eastern Cooperative Oncology Group performance status of 0 or 1 at screening\n* At least one positron emission tomography (PET)-avid measurable lesion according to Modified Lugano Criteria after the last line of therapy.\n* Confirmed histological diagnosis of active relapse/refractory cHL\n* Failed at least 2 prior lines of systemic therapy.\n* No previous treatment with anti-TIM-3.\n* Adequate organ and bone marrow function\n* Non-pregnant women and willingness of female patients to avoid pregnancy or male participants willing to avoid fathering children through highly effective methods of contraception\n* Minimum body weight ≥ 40 kg for all participants.\nHealthy volunteers allowed\nMust have minimum age of 16 Years\nMust have maximum age of 101 Years",
    "exclusion_criteria": "* Unresolved toxicities of ≥ Grade 2 from prior therapy\n* Any prior ≥ Grade 3 imAE while receiving prior checkpoint inhibitor immunotherapy\n* Patients with central nervous system (CNS) involvement or leptomeningeal disease.\n* History of allogeneic stem cell transplant or organ transplantation.\n* Any venous or arterial thromboembolic event within ≤ 6 months prior to the first dose of study intervention.\n* Active infection including Tuberculosis (TB), human immunodeficiency virus (HIV), hepatitis A, chronic or active hepatitis B, chronic or active hepatitis C, active COVID-19 infection\n* History of arrhythmia which is requires treatment, symptomatic or uncontrol led atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia\n* Uncontrolled intercurrent illness.\n* Active or prior documented pathologically confirmed autoimmune or inflammatory disorders.\n* Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD\n* Other invasive malignancy within 2 years prior to screening\n* Congenital long QT syndrome or history of QT prolongation associated with other medications that cannot be changed or discontinued based on a cardiologist assessment\n* Current or prior use of immunosuppressive medication within 14 days prior to the first dose of study intervention\n* Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.",
    "miscellaneous_criteria": ""
}